Ads
related to: treatment drugs for multiple myeloma- Side Effect Info
Learn More About
Possible Side Effects.
- Treatment Results
See Treatment Results
From A Clinical Trial.
- Side Effect Info
Search results
Results from the WOW.Com Content Network
A 2016 study concluded that stem cell transplant is the preferred treatment for multiple myeloma. [107] There are two types of stem cell transplants to treat multiple myeloma. [108] In autologous hematopoietic stem-cell transplantation (ASCT) – the patient's stem cells are collected from the patient's blood. The patient is given high-dose ...
The safety and efficacy of idecabtagene vicleucel were evaluated in a multicenter study of 127 people with relapsed (myeloma that returns after completion of treatment) and refractory (myeloma that does not respond to treatment) multiple myeloma who received at least three prior lines of antimyeloma therapies; 88% had received four or more ...
In the United States before market withdrawal, melphalan flufenamide was indicated in combination with dexamethasone for the treatment of adults with relapsed or refractory multiple myeloma, with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one ...
Tecvayli was first approved in October 2022 for the treatment of adults with multiple myeloma that is hard to treat, or has come back after receiving at least four prior lines of certain classes ...
The safety and effectiveness of elranatamab was evaluated in MagnetisMM-3 (NCT04649359), an open-label, single-arm, multi-center study that included participants with relapsed/refractory multiple myeloma who are refractory to at least one proteasome inhibitor, one immunomodulatory drug, and one anti-CD38 antibody. [12]
In November 2015, the US Food and Drug Administration (FDA) approved daratumumab for treatment of multiple myeloma in people who had received at least three prior therapies. [33] [34] In May 2016 daratumumab was also conditionally approved by the European Medicines Agency for treatment of multiple myeloma. [35]
Ads
related to: treatment drugs for multiple myeloma